386 related articles for article (PubMed ID: 23169287)
21. Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer.
West NR; Milne K; Truong PT; Macpherson N; Nelson BH; Watson PH
Breast Cancer Res; 2011; 13(6):R126. PubMed ID: 22151962
[TBL] [Abstract][Full Text] [Related]
22. Phenotyping of lymphocytes expressing regulatory and effector markers in infiltrating ductal carcinoma of the breast.
Leong PP; Mohammad R; Ibrahim N; Ithnin H; Abdullah M; Davis WC; Seow HF
Immunol Lett; 2006 Feb; 102(2):229-36. PubMed ID: 16246429
[TBL] [Abstract][Full Text] [Related]
23. Nodal status in luminal A invasive breast cancer: relationships with cytotoxic CD8 + and regulatory FOXP3 + cells tumor-associated infiltrate and other prognostic factors.
Glajcar A; Łazarczyk A; Tyrak KE; Hodorowicz-Zaniewska D; Streb J; Okoń K; Szpor J
Virchows Arch; 2021 Nov; 479(5):871-882. PubMed ID: 34117905
[TBL] [Abstract][Full Text] [Related]
24. Association Between FOXP3/CD8 Lymphocyte Ratios and Tumor Infiltrating Lymphocyte Levels in Different Breast Cancer Subtypes.
Fukui R; Fujimoto Y; Watanabe T; Inoue N; Bun A; Higuchi T; Imamura M; Morimoto K; Hirota S; Miyoshi Y
Anticancer Res; 2020 Apr; 40(4):2141-2150. PubMed ID: 32234907
[TBL] [Abstract][Full Text] [Related]
25. Utility of tumour-infiltrating CD25+FOXP3+ regulatory T cell evaluation in predicting local recurrence in vertical growth phase cutaneous melanoma.
Miracco C; Mourmouras V; Biagioli M; Rubegni P; Mannucci S; Monciatti I; Cosci E; Tosi P; Luzi P
Oncol Rep; 2007 Nov; 18(5):1115-22. PubMed ID: 17914561
[TBL] [Abstract][Full Text] [Related]
26. Clinical significance of tumor-infiltrating lymphocytes in breast cancer.
Stanton SE; Disis ML
J Immunother Cancer; 2016; 4():59. PubMed ID: 27777769
[TBL] [Abstract][Full Text] [Related]
27. Stromal regulatory T-cells are associated with a favourable prognosis in gastric cancer of the cardia.
Haas M; Dimmler A; Hohenberger W; Grabenbauer GG; Niedobitek G; Distel LV
BMC Gastroenterol; 2009 Sep; 9():65. PubMed ID: 19732435
[TBL] [Abstract][Full Text] [Related]
28. CD25 identifies a subset of CD4⁺FoxP3⁻ TIL that are exhausted yet prognostically favorable in human ovarian cancer.
deLeeuw RJ; Kroeger DR; Kost SE; Chang PP; Webb JR; Nelson BH
Cancer Immunol Res; 2015 Mar; 3(3):245-53. PubMed ID: 25480168
[TBL] [Abstract][Full Text] [Related]
29. Regulatory T lymphocyte infiltration in metastatic breast cancer-an independent prognostic factor that changes with tumor progression.
Stenström J; Hedenfalk I; Hagerling C
Breast Cancer Res; 2021 Feb; 23(1):27. PubMed ID: 33602289
[TBL] [Abstract][Full Text] [Related]
30. In breast cancer, a high ratio of tumour-infiltrating intraepithelial CD8+ to FoxP3+ cells is characteristic for the medullary subtype.
Anz D; Eiber S; Scholz C; Endres S; Kirchner T; Bourquin C; Mayr D
Histopathology; 2011 Nov; 59(5):965-74. PubMed ID: 22092408
[TBL] [Abstract][Full Text] [Related]
31. Association of Notch pathway down-regulation with Triple Negative/Basal-like breast carcinomas and high tumor-infiltrating FOXP3+ Tregs.
Ortiz-Martínez F; Gutiérrez-Aviñó FJ; Sanmartín E; Pomares-Navarro E; Villalba-Riquelme C; García-Martínez A; Lerma E; Peiró G
Exp Mol Pathol; 2016 Jun; 100(3):460-8. PubMed ID: 27118257
[TBL] [Abstract][Full Text] [Related]
32. The Prognostic Value of FoxP3+ Tumour-Infiltrating Lymphocytes in Rectal Cancer Depends on Immune Phenotypes Defined by CD8+ Cytotoxic T Cell Density.
Schnellhardt S; Hirneth J; Büttner-Herold M; Daniel C; Haderlein M; Hartmann A; Fietkau R; Distel L
Front Immunol; 2022; 13():781222. PubMed ID: 35140715
[TBL] [Abstract][Full Text] [Related]
33. Tumour-infiltrating CD4-, CD8- and FOXP3-positive immune cells as predictive markers of mortality in BRCA1- and BRCA2-associated breast cancer.
Jørgensen N; Hviid TVF; Nielsen LB; Sønderstrup IMH; Eriksen JO; Ejlertsen B; Gerdes AM; Kruse TA; Thomassen M; Jensen MB; Lænkholm AV
Br J Cancer; 2021 Nov; 125(10):1388-1398. PubMed ID: 34365471
[TBL] [Abstract][Full Text] [Related]
34. Differential pattern and prognostic significance of CD4+, FOXP3+ and IL-17+ tumor infiltrating lymphocytes in ductal and lobular breast cancers.
Droeser R; Zlobec I; Kilic E; Güth U; Heberer M; Spagnoli G; Oertli D; Tapia C
BMC Cancer; 2012 Apr; 12():134. PubMed ID: 22471961
[TBL] [Abstract][Full Text] [Related]
35. A high CD8 to FOXP3 ratio in the tumor stroma and expression of PTEN in tumor cells are associated with improved survival in non-metastatic triple-negative breast carcinoma.
Tavares MC; Sampaio CD; Lima GE; Andrade VP; Gonçalves DG; Macedo MP; Cordeiro de Lima VC
BMC Cancer; 2021 Aug; 21(1):901. PubMed ID: 34362334
[TBL] [Abstract][Full Text] [Related]
36. Levels of different subtypes of tumour-infiltrating lymphocytes correlate with each other, with matched circulating lymphocytes, and with survival in breast cancer.
Verma R; Hanby AM; Horgan K; Verghese ET; Volpato M; Carter CR; Hughes TA
Breast Cancer Res Treat; 2020 Aug; 183(1):49-59. PubMed ID: 32577938
[TBL] [Abstract][Full Text] [Related]
37. CD4/CD8 + T cells, DC subsets, Foxp3, and IDO expression are predictive indictors of gastric cancer prognosis.
Li F; Sun Y; Huang J; Xu W; Liu J; Yuan Z
Cancer Med; 2019 Dec; 8(17):7330-7344. PubMed ID: 31631566
[TBL] [Abstract][Full Text] [Related]
38. Regulatory and memory T lymphocytes infiltrating prostate tumors predict long term clinical outcomes.
Molina OE; LaRue H; Simonyan D; Hovington H; Vittrant B; Têtu B; Fradet V; Lacombe L; Bergeron A; Fradet Y
Front Immunol; 2024; 15():1372837. PubMed ID: 38887294
[TBL] [Abstract][Full Text] [Related]
39. The presence of tumour-infiltrating lymphocytes (TILs) and the ratios between different subsets serve as prognostic factors in advanced hypopharyngeal squamous cell carcinoma.
Wang J; Tian S; Sun J; Zhang J; Lin L; Hu C
BMC Cancer; 2020 Aug; 20(1):731. PubMed ID: 32758195
[TBL] [Abstract][Full Text] [Related]
40. Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer.
de Jong RA; Leffers N; Boezen HM; ten Hoor KA; van der Zee AG; Hollema H; Nijman HW
Gynecol Oncol; 2009 Jul; 114(1):105-10. PubMed ID: 19411095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
